BAO PHARMA-B(02659): Injectable hyaluronidase approved by the National Medical Products Administration for listing.

BAO PHARMA-B (02659) announced that on March 31, 2026, the company's independently developed and leading injection hyaluronidase in China (Bao Shuyi, project code KJ017), with a specification of 385U per bottle, has been approved for market by the National Medical Products Administration. It is used to assist in subcutaneous infusion (such as saline injection and lactated Ringer's injection). KJ017 is a highly glycosylated recombinant human hyaluronidase that specifically breaks down hyaluronic acid in subcutaneous tissue, temporarily and locally increasing the permeability of the extracellular matrix of subcutaneous tissue. This enables safe, rapid, and large volume subcutaneous administration, providing a new option for difficult-to-dose patients with difficult venous access. Compared to traditional animal-derived hyaluronidase (which carries the risk of allergies, requires skin testing before use, and has unstable quality between batches), KJ017 utilizes genetic recombination technology and controlled production processes to achieve highly consistent quality between batches, improve safety, and significantly reduce the risk of immunogenicity. It does not require skin testing before use, enhancing the convenience and safety of clinical use.